Or. Admin. Code § 855-115-0345

Current through Register Vol. 63, No. 12, December 1, 2024

Section 855-115-0345 - [Effective 2/4/2025] Services: Prescribing - Protocol Compendium

A Pharmacist may prescribe, according to OAR 855-115-0330 and OAR 855-115-0335, FDA-approved drugs and devices listed in the following compendium, pursuant to a statewide drug therapy management protocol.

(1) Continuation of therapy including emergency refills of insulin and early refills of opioid use disorder medications (v. 08/2024)

(2) Conditions

(a) Cough and cold symptom management

(A) Benzonatate (v. 06/2021);

(B) Short-acting beta agonists (v. 06/2021);

(C) Intranasal corticosteroids (v. 06/2021);

(b) Vulvovaginal candidiasis (VVC) (v. 06/2021);

(c) COVID-19 Antigen Self-Test (v. 12/2021);

(d) SARS-CoV-2 Antiviral (v. 08/2024)

(3) Preventative care

(a) Emergency Contraception (v. 06/2021);

(b) Male and female condoms (v. 06/2021);

(c) Tobacco Cessation, NRT (Nicotine Replacement Therapy) and Non-NRT (v. 06/2024);

(d) Travel Medications (v. 06/2024);

(e) HIV Post-exposure Prophylaxis (PEP) (v. 06/2023);

(f) HIV Pre-exposure Prophylaxis (PrEP) (v.06/2023);

(g) Contraception (v. 06/2023);

(h) Sexually Transmitted Infections Post-exposure Prophylaxis (STI PEP) (v. 06/2024);

(i) Short-acting Opioid Antagonists (v. 06/2024); and

(j) Vaccines:

(A) Standard Protocol for All Vaccines: Cover Page & Assessment and Treatment Care Pathway (v. 06/2024);

(B) Standard Protocol for All Vaccines: Managing Adverse Reactions (v. 06/2024);

(C) Cholera (v. 02/2024);

(D) Coronavirus 2019 (v. 06/2024);

(E) Haemophilus Influenza type b (v. 06/2024);

(F) Hepatitis A containing vaccines (v. 02/2024);

(G) Hepatitis B containing vaccines (v. 02/2024);

(H) Human Papillomavirus (v. 02/2024);

(I) Influenza - Inactivated Influenza Vaccines and Recombinant Influenza Vaccines 2023-24 (v. 06/2024);

(J) Influenza - Live Attenuated Influenza Vaccine 2023-24 (v. 02/2024);

(K) Japanese Encephalitis (v. 06/2024);

(L) Meningococcal containing vaccines (v. 06/2024);

(M) Measles Mumps & Rubella containing vaccines (v. 02/2024);

(N) Pneumococcal (v. 06/2024);

(O) Polio (v. 06/2024);

(P) Rabies (v. 02/2024);

(Q) Respiratory Syncytial Virus (v. 06/2024);

(R) Tetanus Diphtheria containing vaccines (v. 06/2024);

(S) Typhoid (v. 02/2024);

(T) Varicella containing vaccines (v. 02/2024);

(U) Yellow fever (v. 06/2024); and

(V) Zoster (v. 02/2024).

Or. Admin. Code § 855-115-0345

BP 16-2023, adopt filed 08/16/2023, effective 3/1/2024; BP 14-2024, temporary amend filed 03/01/2024, effective 3/1/2024 through 8/27/2024; BP 25-2024, temporary amend filed 03/04/2024, effective 3/4/2024 through 8/30/2024; BP 54-2024, amend filed 06/18/2024, effective 6/20/2024; BP 61-2024, temporary amend filed 08/09/2024, effective 8/9/2024 through 2/4/2025; BP 59-2024, amend filed 08/09/2024, effective 8/9/2024

Publications: Publications referenced are available from the agency.

Statutory/Other Authority: ORS 689.205, 2024 HB 4002, 2024 SB 1506

Statutes/Other Implemented: ORS 689.645, ORS 689.649, ORS 689.689, 2024 HB 4002, 2024 SB 1506